Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 29, 2024

Real-World Effectiveness of Nivolumab Monotherapy in Patients With Advanced Gastric Cancer

The Oncologist

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08)
Oncologist 2024 Apr 06;[EPub Ahead of Print], Y Sunakawa, Y Sakamoto, R Kawabata, A Ishiguro, Y Akamaru, Y Kito, M Takahashi, J Matsuyama, H Yabusaki, A Makiyama, T Suzuki, M Tsuda, H Yasui, J Hihara, A Takeno, E Inoue, W Ichikawa, M Fujii

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading